Bispecific EGFR/HER3-targeted antibody–drug conjugate that binds EGFR- and HER3-expressing tumor cells, is internalized, and releases a camptothecin-class topoisomerase I inhibitor (brengitecan) to induce DNA damage and tumor cell death, with potential bystander effect.